Onward Company Introduction

## Onward Therapeutics

Onward Therapeutics is a development stage oncology company, focusing on the identification and development of innovative cancer therapies. The company, led by an experienced team in drug development, adopts a **"**Buy-to-Build**"** business model of licensing development candidates and/or investing in its partners with platform technologies. The company, which is headquartered in Switzerland and also operates from France and Taiwan, has raised CHF 75.5M (~USD 82M) since its inception in late 2019. It is actively developing its clinical candidates while seeking new development projects and preparing for its Series B financing round in 2024.

Onward Therapeutics is advancing its two lead programs, a bispecific antibody (OT-A201) and a NK cell-based therapeutic platform (NK-001 as its first product) acquired from strategic investments (including worldwide license) made in Biomunex Pharmaceuticals and Emercell in 2021. Thanks to its experienced project execution team, Onward Therapeutics expects to enter clinical development stage for these two projects in the next few months.

## OT-A201

OT-A201 is a first-in-class humanized bispecific antibody, targeting two immune checkpoints being evaluated as a potential new treatment for advanced hematological malignancies and solid tumors. In preclinical studies, OT-A201 was shown to be very specific and safe while displaying efficient anti-tumor activity in vivo. The upcoming Phase 1 is a multi-center and open-label study that will be conducted in Europe to evaluate the safety, tolerability and preliminary efficacy of OT-A201.

## NK-001

NK-001 is the first candidate from Onward Therapeutics' off-the-shelf NK cell-based therapeutic platform. It is a standardized, robust, and non-clonal allogeneic product derived from umbilical cord blood according to a patented process. As a simple and safe product, it has the versatility to be combined with other targeted therapies especially antibodies in both hematological and solid tumor indications. The program, currently in IND-enabling stage, will enter the clinic in early 2024.

Onward Therapeutics SA
Biopôle, bâtiment Lysine
Route de la Corniche 4
1066 Epalinges, Switzerland

Onward Therapeutics France SAS
77 rue de Vaugirard
75006 Paris, France